Does schisandra actually protect the liver, or just lower a number?

The evidence is for lower ALT and AST, which indicates less ongoing hepatocyte injury. There is no trial evidence that it reduces fibrosis or changes long-term outcomes.

How long before liver enzymes change?

Trials generally recheck at eight to twelve weeks. Repeat testing with your doctor is the only meaningful way to know whether it is doing anything.

Is it safe with prescription medicines?

Often not. Schisandra inhibits CYP3A4 and P-glycoprotein and can substantially raise levels of immunosuppressants, statins and sedatives. Check with a pharmacist before combining.

A synthetic analogue of schisandrin C, licensed as a hepatoprotective drug in China. Much of the clinical evidence often cited for schisandra actually concerns this derivative.

Outcome

Moderate Evidence

Schisandra for Liver Protection

Schisandra lignans consistently lower ALT and AST across clinical studies, and a synthetic analogue is a licensed hepatoprotective drug in China.

Overview

Schisandra chinensis is one of the few botanicals with a genuine pharmaceutical lineage in liver disease. Its lignans were the starting point for bifendate (DDB), a synthetic schisandrin C analogue licensed in China as a hepatoprotective drug, and much of the clinical literature concerns that derivative rather than the berry itself. Across those studies the consistent finding is reduced ALT and AST in chronic hepatitis and drug-induced liver injury.

The important limitation is what the endpoint measures. Lower transaminases mean less ongoing hepatocyte injury; they do not demonstrate reduced fibrosis, and in the bifendate literature enzyme rebound after stopping has been documented. Most trials are small, Chinese-language and of variable methodological quality. Schisandra is therefore a reasonable adjunct where the cause of liver injury has already been identified and is being managed - not a substitute for diagnosis.

How It Works

Schisandrin B, the most studied lignan, activates Nrf2 signalling in hepatocytes. This upregulates glutathione S-transferase, glutathione reductase and other phase II antioxidant enzymes, raising the cell's capacity to neutralise reactive intermediates generated during drug metabolism and inflammation.

A second arm of the mechanism is heat-shock protein 70 induction, which stabilises hepatocyte proteins under oxidative stress and reduces apoptotic signalling. Schisandra also modulates several cytochrome P450 isoforms - useful in animal models of paracetamol toxicity, but the same property is the source of its most serious drug interactions in humans. That dual character matters: the mechanism that protects hepatocytes in a rat model is the mechanism that raises tacrolimus levels several-fold in a transplant patient.

Dosing & Protocol

Standardisation is the whole game with schisandra, because berry powders vary widely in lignan content. Start at roughly 1.5 g per day of dried berry equivalent, or an extract providing about 100 mg of schisandrins, taken with food. Increase to 200 mg of schisandrins or up to 6 g of dried berry as tolerated, and recheck liver function tests at eight to twelve weeks with your doctor rather than continuing indefinitely on faith.

Evidence

The linked systematic review below synthesises clinical studies of schisandra extract on liver enzymes and hepatic function. Read it alongside the caveat that ALT and AST are process markers: they track ongoing injury, not the structural outcome that determines prognosis.

Only studies already linked to this pairing are shown.

Schisandra chinensis extract improves liver enzymes and hepatic function: a systematic review of clinical studies

Score: 7/10

2021

systematic_review

Kopustinskiene DM, Bernatoniene J

Schisandra lignans consistently reduced serum ALT and AST, and the analogue bicyclol is licensed as a hepatoprotective drug.

View source

Safety

Schisandra is generally well tolerated, with heartburn, indigestion, reduced appetite and occasional skin rash the reported adverse effects. It has uterine stimulant activity and must be avoided in pregnancy; breastfeeding safety is unknown. It should also be avoided in epilepsy, peptic ulcer disease and raised intracranial pressure.

Abnormal liver enzymes need a cause identified, not just a number lowered. Fatty liver, alcohol, hepatitis B and C, autoimmune hepatitis, haemochromatosis and drug effects all require different management. Jaundice, dark urine, pale stools, right upper abdominal pain, easy bruising or abdominal swelling need prompt medical assessment.

Interactions & Conflicts

Schisandra is a clinically significant inhibitor of CYP3A4 and P-glycoprotein, and human studies have shown several-fold increases in tacrolimus exposure. This is not a theoretical interaction - it is the single most important reason to avoid schisandra without specialist advice if you take narrow-therapeutic-index drugs.

Severity	Mechanism	Action
high	—	Avoid unless supervised by the transplant team
high	—	Avoid or seek prescriber advice
moderate	—	Avoid combination
high	—	Do not use

References

Frequently Asked Questions

Medical Disclaimer

The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.